Valeant Pharmaceuticals International, Inc. (VRX) Reports Q2 Earnings of $1.01; Guides Slightly Higher
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q2 EPS of $1.01, versus $0.99 reported last year. Revenue for the quarter came in at $820.1 million versus the consensus estimate of $822.7 million.
Valeant Pharmaceuticals International, Inc. sees FY2012 EPS of $4.55-$4.75, versus prior guidance of $4.45-$4.70 and the consensus of $4.51
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Valeant Pharmaceuticals International, Inc. sees FY2012 EPS of $4.55-$4.75, versus prior guidance of $4.45-$4.70 and the consensus of $4.51
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.